GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soleno Therapeutics Inc (NAS:SLNO) » Definitions » Market Cap

Soleno Therapeutics (Soleno Therapeutics) Market Cap : $1,679.40 Mil (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Soleno Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Soleno Therapeutics's share price for the quarter that ended in Mar. 2024 was $42.8. Soleno Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 33.34 Mil. Therefore, Soleno Therapeutics's market cap for the quarter that ended in Mar. 2024 was $1,426.83 Mil.

Soleno Therapeutics's quarterly market cap increased from Sep. 2023 ($456.44 Mil) to Dec. 2023 ($1,275.05 Mil) and increased from Dec. 2023 ($1,275.05 Mil) to Mar. 2024 ($1,426.83 Mil).

Soleno Therapeutics's annual market cap declined from Dec. 2021 ($32.74 Mil) to Dec. 2022 ($16.16 Mil) but then increased from Dec. 2022 ($16.16 Mil) to Dec. 2023 ($1,275.05 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Soleno Therapeutics's Enterprise Value for Today is $1,496.21 Mil.


Soleno Therapeutics Market Cap Historical Data

The historical data trend for Soleno Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soleno Therapeutics Market Cap Chart

Soleno Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.29 153.66 32.74 16.16 1,275.05

Soleno Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.48 42.65 456.44 1,275.05 1,426.83

Competitive Comparison of Soleno Therapeutics's Market Cap

For the Biotechnology subindustry, Soleno Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soleno Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soleno Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Soleno Therapeutics's Market Cap falls into.



Soleno Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Soleno Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$40.25*31.6782
=$1,275.05

Soleno Therapeutics's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$42.8*33.3371
=$1,426.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Soleno Therapeutics  (NAS:SLNO) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Soleno Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Soleno Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Soleno Therapeutics (Soleno Therapeutics) Business Description

Traded in Other Exchanges
Address
203 Redwood Shores Parkway, Suite 500, Redwood City, CA, USA, 94065
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome.
Executives
Patricia C Hirano officer: See Remarks 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Kristen Yen officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
Bhatnagar Anish director, officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
James H Mackaness officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Abingworth Bioventures Vii Lp 10 percent owner PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505

Soleno Therapeutics (Soleno Therapeutics) Headlines

From GuruFocus